N@N

Repligen Announces Robert A. Spurr Joins Company as Senior Vice President of Sales and Marketing and Chief Commercial Officer

^{Published on 2011-08-11 11:00:59 - Market Wire}
 

WALTHAM, Mass.--([ BUSINESS WIRE ])--Repligen Corporation (NASDAQ: RGEN) announced today that Robert A. Spurr has joined the Company as Senior Vice President of Sales and Marketing and Chief Commercial Officer. Mr. Spurr brings to Repligen more than 25 years of commercial experience in the sales and marketing of imaging and pharmaceutical products. In this new role, Mr. Spurr will be responsible for all commercial activities for the Company including establishing the commercial organization to sell SecreFloa" in the U.S. pending approval by the FDA and overseeing the commercial operations of our bioprocessing business including expanding the sales of our recently launched Opusa" product line to biopharmaceutical customers.

"Boba™s history of accomplishments and experience in leading successful commercial organizations and product launches will be of significant value to the company as we pursue FDA and EMA approval and commercialization of our first imaging product and we continue to expand our bioprocessing business through internal development and product acquisition."

aWe are very pleased to welcome an experienced executive like Bob to the senior management team at this pivotal time as we transition Repligen from a development stage company to an integrated organization with commercial, manufacturing and product development capabilities,a stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. aBoba™s history of accomplishments and experience in leading successful commercial organizations and product launches will be of significant value to the company as we pursue FDA and EMA approval and commercialization of our first imaging product and we continue to expand our bioprocessing business through internal development and product acquisition.a

Mr. Spurr has held numerous executive level positions including Vice President of Sales and Marketing for Ortho-McNeil, a division of Johnson and Johnson, where he was responsible for $750 million in annual revenue and most recently, he led the commercial efforts of Lantheus Medical Imaging as Vice President of Sales and Marketing where he was responsible for a $400 million radiopharmaceutical business.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology. We have a core competency in the development and manufacturing of biologics products, which is the basis for our bioprocessing business and we have out-licensed certain biologics intellectual property, which provide ongoing sources of revenue. Repligena™s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested at [ www.repligen.com ].

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding future financial performance and position, managementa™s strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property protection, product development, manufacturing plans and performance, projected changes in the size of our markets, our market share and product sales and other statements identified by words like abelieve,a aexpect,a amay,a awill,a ashould,a aseek,a or acoulda and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of our clinical trials; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; the success of current and future collaborative relationships; the market acceptance of our products; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation of incurring continued losses; our uncertainty of product revenues and profits; our ability to generate future revenues; our ability to raise additional capital to continue our drug development programs; our compliance with all Food and Drug Administration regulations; our ability to obtain; maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales and manufacturing capabilities; our dependence on third-party manufacturers and value added resellers; our ability to hire and retain skilled personnel; our volatile stock price; and other risks detailed in Repligena™s annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect managementa™s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.